Enhertu is a combination of a chemotherapy drug and targeted therapy ... Doctors may prescribe other forms of treatment besides chemo and immunotherapy for some cancers. Are chemotherapy and ...

The data – presented in a keynote at the ESMO cancer congress – also showed a three-fold improvement in progression-free survival – 25.1 months for Enhertu versus 7.2 months for Roche's drug ...

that could see the drug being used in advanced breast cancer with even lower levels of the HER2 biomarker. The marketing application for Enhertu (trastuzumab deruxtecan) is based on the results of ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for ...